Advertisement
Advertisement
BNTX
BioNTech SE - ADR
91.31
USDSponsored
+1.21
+1.35%
Mar 13, 16:00 UTC -4
Closed
After-Market
90.94
-0.38
-0.41%
BNTX Earnings Reports
Positive Surprise Ratio
BNTX beat 17 of 26 last estimates.
65%
Next Report
Date of Next Report
May 05, 2026
Estimate for Q1 26 (Revenue/ EPS)
$297.06M
/-$1.99
Implied change from Q4 25 (Revenue/ EPS)
-67.25%
/+521.88%
Implied change from Q1 25 (Revenue/ EPS)
+62.51%
/+15.03%
BioNTech SE - ADR earnings per share and revenue
On Mar 10, 2026, BNTX reported earnings of -0.32 USD per share (EPS) for Q4 25, missing the estimate of -0.18 USD, resulting in a -72.12% surprise. Revenue reached 907.17 million, compared to an expected 758.80 million, with a 19.55% difference. The market reacted with a -17.88% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -1.99 USD, with revenue projected to reach 297.06 million USD, implying an increase of 521.88% EPS, and decrease of -67.25% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mineralys Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.40
Surprise
+26.40%
Corvus Pharmaceuticals, Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.13
Actual
-$0.15
Surprise
-13.72%
Pharming Group N.V. ADS, each representing 10 ordinary shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.00
Actual
$0.01
Surprise
+16.28%
ADC Therapeutics SA
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.04
Surprise
+85.39%
Kamada Ltd
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.07
Actual
$0.06
Surprise
-24.15%
Allogene Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.22
Actual
-$0.17
Surprise
+22.73%
Molecular Partners AG - ADR
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.32
Surprise
+7.09%
Whitehawk Therapeutics, Inc. Common Stock
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.15
Actual
-$0.34
Surprise
-116.42%
Codexis, Inc.
Report Date
Mar 11, 2026 For Q4 25
Estimate
-$0.04
Actual
$0.11
Surprise
+357.01%
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
FAQ
What were BioNTech SE - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, BioNTech SE - ADR reported EPS of -$0.32, missing estimates by -72.12%, and revenue of $907.17M, 19.55% above expectations.
How did the market react to BioNTech SE - ADR's Q4 2025 earnings?
The stock price moved down -17.88%, changed from $102.16 before the earnings release to $83.89 the day after.
When is BioNTech SE - ADR expected to report next?
The next earning report is scheduled for May 05, 2026.
What are the forecasts for BioNTech SE - ADR's next earnings report?
Based on 7
analysts, BioNTech SE - ADR is expected to report EPS of -$1.99 and revenue of $297.06M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement